Who are EV71 vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Havrix (HAV), Hepatitis A (control), Havrix+Healive, IPV at 6 weeks of age, Havrix Junior, fIPV (0.2mL) IM.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ev71-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

EV71 vaccine — Competitive Intelligence Brief

EV71 vaccine (EV71 vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: inactivated viral vaccine. Area: Immunology / Infectious Disease.

marketed inactivated viral vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

EV71 vaccine (EV71 vaccine) — Sinovac Biotech Co., Ltd. The EV71 vaccine stimulates the immune system to produce antibodies and cellular immunity against enterovirus 71, preventing infection and disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
EV71 vaccine TARGET	EV71 vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated viral vaccine
Havrix (HAV)	Havrix (HAV)	Pfizer	marketed	Inactivated viral vaccine	Hepatitis A virus antigen
Hepatitis A (control)	Hepatitis A (control)	International Vaccine Institute	marketed	inactivated viral vaccine	Hepatitis A virus surface antigens
Havrix+Healive	Havrix+Healive	Sinovac Biotech Co., Ltd	marketed	Combination inactivated viral vaccine	Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg)
IPV at 6 weeks of age	IPV at 6 weeks of age	Centers for Disease Control and Prevention	marketed	Inactivated viral vaccine	Poliovirus types 1, 2, and 3
Havrix Junior	Havrix Junior	GlaxoSmithKline	marketed	Inactivated viral vaccine	Hepatitis A virus antigen
fIPV (0.2mL) IM	fIPV (0.2mL) IM	Centers for Disease Control and Prevention	marketed	Inactivated viral vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (inactivated viral vaccine class)

Sinovac Biotech Co., Ltd · 5 drugs in this class
Sinovac Research and Development Co., Ltd. · 2 drugs in this class
Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
Federal University of Espirito Santo · 1 drug in this class
International Vaccine Institute · 1 drug in this class
MacroGenics · 1 drug in this class
Shandong Province Centers for Disease Control and Prevention · 1 drug in this class
Beijing Chaoyang District Centre for Disease Control and Prevention · 1 drug in this class
Zhejiang Provincial Center for Disease Control and Prevention · 1 drug in this class
Centers for Disease Control and Prevention · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EV71 vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/ev71-vaccine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab